This observational study is looking at how the gut microbiome (the community of bacteria in your intestines) might be connected to how well immunotherapy works for women with advanced or recurrent gynecological cancer. Researchers will collect samples like stool, blood, vaginal swabs, and oral swabs from about 30 participants before, during, and after their immunotherapy treatment. By analyzing these samples, they hope to understand how changes in the gut microbiome relate to the effectiveness of checkpoint inhibitor immunotherapy. This information could help design future studies to improve treatment for gynecological cancer patients.

Study design

This is an observational study involving about 30 participants. It is not specified if it is randomized or blinded.

What's involved

You would provide fecal, blood, vaginal swab, and oral mucosal swab samples at three different times: before treatment, after four doses of immunotherapy, and at the end of immunotherapy. You would also complete a food dietary questionnaire.

Compensation

Not stated in the trial record.

Follow-up

Microbiome changes will be measured through analysis of biological samples over approximately two years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.